Scot Ebbinghaus

27.3k total citations · 2 hit papers
97 papers, 6.7k citations indexed

About

Scot Ebbinghaus is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Scot Ebbinghaus has authored 97 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Oncology, 54 papers in Molecular Biology and 19 papers in Immunology. Recurrent topics in Scot Ebbinghaus's work include Cancer Immunotherapy and Biomarkers (53 papers), CAR-T cell therapy research (37 papers) and Melanoma and MAPK Pathways (20 papers). Scot Ebbinghaus is often cited by papers focused on Cancer Immunotherapy and Biomarkers (53 papers), CAR-T cell therapy research (37 papers) and Melanoma and MAPK Pathways (20 papers). Scot Ebbinghaus collaborates with scholars based in United States, France and Canada. Scot Ebbinghaus's co-authors include Laurence H. Hurley, Antoni Ribas, Adil Daud, Caroline Robert, Omid Hamid, Anthony M. Joshua, F. Stephen Hodi, Soonmo Peter Kang, Jennifer J. Knox and Stephen L. Chan and has published in prestigious journals such as The Lancet, Journal of the American Chemical Society and Nucleic Acids Research.

In The Last Decade

Scot Ebbinghaus

93 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

2019 1.3k citations Richard S. Finn, Baek‐Yeol Ryoo et al. Journal of Clinical Oncology profile →
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

2017 898 citations Jacob Schachter, Antoni Ribas et al. The Lancet profile →

Peers

Scot Ebbinghaus

ONCOL

IMMUN

HEPAT

PRM

Aiwu Ruth He United States

E. Gabriela Chiorean United States

Lia Gore United States

Matthew H. Taylor United States

Anthony B. El-Khoueiry United States

Michael J. Pishvaian United States

Allen Lee Cohn United States

Aaron Pollett Canada

Peter Langmuir United States

Teresa Macarulla Spain

Aiwu Ruth He United States

Scot Ebbinghaus

2.2k ×0.6

ONCOL

1.5k ×0.6

722 ×0.4

IMMUN

1.4k ×1.3

HEPAT

698 ×0.7

PRM

Citations per year, relative to Scot Ebbinghaus Scot Ebbinghaus (= 1×) peers Aiwu Ruth He

Countries citing papers authored by Scot Ebbinghaus

Since Specialization

Citations

This map shows the geographic impact of Scot Ebbinghaus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scot Ebbinghaus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scot Ebbinghaus more than expected).

Fields of papers citing papers by Scot Ebbinghaus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scot Ebbinghaus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scot Ebbinghaus. The network helps show where Scot Ebbinghaus may publish in the future.

Co-authorship network of co-authors of Scot Ebbinghaus

This figure shows the co-authorship network connecting the top 25 collaborators of Scot Ebbinghaus. A scholar is included among the top collaborators of Scot Ebbinghaus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scot Ebbinghaus. Scot Ebbinghaus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ebbinghaus, Scot, et al.. (2024). The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab. Drugs. 84(12). 1579–1601.

Finn, Richard S., Baek‐Yeol Ryoo, Philippe Merle, et al.. (2019). Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 38(3). 193–202. 1300 indexed citations breakdown →

Geoerger, Birgit, Hyoung Jin Kang, Michal Yalon-Oren, et al.. (2019). Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. The Lancet Oncology. 21(1). 121–133. 208 indexed citations

Finn, Richard S., Baek‐Yeol Ryoo, Philippe Merle, et al.. (2019). Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. Annals of Oncology. 30. iv135–iv136. 8 indexed citations

Turner, David C., Anna Kondic, Keaven M. Anderson, et al.. (2018). Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clinical Cancer Research. 24(23). 5841–5849. 156 indexed citations

Hamid, Omid, Caroline Robert, Antoni Ribas, et al.. (2018). Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. British Journal of Cancer. 119(6). 670–674. 117 indexed citations

Robert, Caroline, Antoni Ribas, Omid Hamid, et al.. (2017). Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 36(17). 1668–1674. 336 indexed citations

Hamid, Omid, Igor Puzanov, Reinhard Dummer, et al.. (2017). Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer. 86. 37–45. 135 indexed citations

Schachter, Jacob, Antoni Ribas, Georgina V. Long, et al.. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet. 390(10105). 1853–1862. 898 indexed citations breakdown →

10.

Baselga, José, Serafín Morales, Ahmad Awada, et al.. (2017). A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 163(3). 535–544. 16 indexed citations

11.

Hamid, Omid, Igor Puzanov, Reinhard Dummer, et al.. (2016). Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology. 27. vi379–vi379. 21 indexed citations

12.

Khoja, Leila, Marcus O. Butler, Soonmo Peter Kang, Scot Ebbinghaus, & Anthony M. Joshua. (2015). Pembrolizumab. Journal for ImmunoTherapy of Cancer. 3(1). 36–36. 173 indexed citations

13.

Cosimo, Serena Di, Sriram Sathyanarayanan, Johanna C. Bendell, et al.. (2014). Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial. Clinical Cancer Research. 21(1). 49–59. 48 indexed citations

14.

Meulenbeld, Hielke J., Johann S. de Bono, Scott T. Tagawa, et al.. (2013). Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemotherapy and Pharmacology. 72(4). 909–916. 20 indexed citations

15.

Haines, Brian B., Michael J. Wick, Kyriakos P. Papadopoulos, et al.. (2012). Abstract 1868: Response biomarkers to IGF1R and mTOR inhibitor combination therapy in ovarian carcinoma. Cancer Research. 72(8_Supplement). 1868–1868. 1 indexed citations

16.

Ziemba, Amy, et al.. (2005). Targeting and Regulation of the HER-2/neu Oncogene Promoter with Bis-Peptide Nucleic Acids. Oligonucleotides. 15(1). 36–50. 7 indexed citations

17.

Ziemba, Amy, et al.. (2005). Peptide Nucleic Acid Conjugates: Synthesis, Properties and Applications. Current Topics in Medicinal Chemistry. 5(12). 1119–1131. 31 indexed citations

18.

Wood, Stacey, et al.. (2005). Evidence for the Presence of a Guanine Quadruplex Forming Region within a Polypurine Tract of the Hypoxia Inducible Factor 1α Promoter. Biochemistry. 44(49). 16341–16350. 241 indexed citations

19.

Ebbinghaus, Scot & Michael S. Gordon. (2004). Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematology/Oncology Clinics of North America. 18(5). 1143–1159. 7 indexed citations

20.

Ebbinghaus, Scot, Guillermo A. Herrera, & M. Ernest Marshall. (1995). Rhabdoid Tumor of the Kidney in an Adult: Review of the Literature and Report of a Case Responding to Interleukin-2. PubMed. 10(3). 237–241. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact